Suppr超能文献

入院时高血糖对接受重组组织型纤溶酶原激活剂治疗的患者卒中结局的影响。

Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.

作者信息

Alvarez-Sabín José, Molina Carlos A, Montaner Joan, Arenillas Juan F, Huertas Rafael, Ribo Marc, Codina Agusti, Quintana Manuel

机构信息

Cerebrovascular Unit, Department of Neurology, Hospital Vall d'Hebrón, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

出版信息

Stroke. 2003 May;34(5):1235-41. doi: 10.1161/01.STR.0000068406.30514.31. Epub 2003 Apr 3.

Abstract

BACKGROUND AND PURPOSE

We sought to investigate the impact of hyperglycemia before reperfusion on long-term outcome in patients treated with intravenous tissue plasminogen activator (tPA).

METHODS

Of 268 consecutive patients with a nonlacunar middle cerebral artery (MCA) stroke evaluated at <3 hours after onset, 73 (27.2%) received intravenous tPA. Serum glucose was determined at baseline before tPA administration. Hyperglycemia was defined as a glucose level >140 mg/dL. National Institutes of Health Stroke Scale (NIHSS) scores were obtained at baseline and 24 hours. Transcranial Doppler monitoring of recanalization and reocclusion was conducted during the first 24 hours. Total infarct volume was measured on CT at day 5 to 7. Modified Rankin Scale was used to assess outcome at 3 months.

RESULTS

Median NIHSS score was 17. At baseline, 31 patients (42.5%) were hyperglycemic and 42 (57.5%) normoglycemic. Early reperfusion (<6 hours) occurred in 43 patients (58.9%). Admission blood glucose correlated negatively with the degree of neurological improvement at 24 hours in reperfused (r=-0.43; P=0.019) but not in nonreperfused (r=-0.20; P=0.21) tPA-treated patients. Increased age (P=0.014), history of diabetes mellitus (P=0.043), admission glucose >140 mg/dL (P=0.002), and early reocclusion (P=0.004) were factors associated with poor outcome among reperfused patients. A logistic regression modeling revealed that only admission glucose value >140 mg/dL (odds ratio, 8.4; 95% CI, 1.76 to 40.02; P=0.005) emerged as an independent predictor of poor outcome despite tPA-induced recanalization. In patients with 6-hour persistent MCA occlusion, baseline NIHSS score >15 points (P=0.011) and proximal MCA occlusion (P=0.039) were variables associated with poor outcome on univariate analysis. In a logistic regression model, only NIHSS score >15 points (odds ratio, 11.9; 95% CI, 1.48 to 97.1; P=0.032) remained as an independent predictor of poor outcome and functional dependence at 3 months in nonreperfused tPA-treated patients.

CONCLUSIONS

Hyperglycemia before reperfusion may in part counterbalance the beneficial effect of early restoration of blood flow, which translates into a worse outcome in hyperglycemic patients despite tPA-induced recanalization.

摘要

背景与目的

我们试图研究再灌注前高血糖对接受静脉注射组织型纤溶酶原激活剂(tPA)治疗患者长期预后的影响。

方法

在268例发病后<3小时接受评估的非腔隙性大脑中动脉(MCA)卒中连续患者中,73例(27.2%)接受了静脉注射tPA。在tPA给药前测定基线血清葡萄糖水平。高血糖定义为血糖水平>140mg/dL。在基线和24小时时获取美国国立卫生研究院卒中量表(NIHSS)评分。在最初24小时内进行经颅多普勒监测再通和再闭塞情况。在第5至7天通过CT测量总梗死体积。使用改良Rankin量表评估3个月时的预后。

结果

NIHSS评分中位数为17分。在基线时,31例患者(42.5%)为高血糖,42例(57.5%)为血糖正常。43例患者(58.9%)出现早期再灌注(<6小时)。在接受tPA治疗且实现再灌注的患者中,入院血糖与24小时时神经功能改善程度呈负相关(r=-0.43;P=0.019),但在未实现再灌注的患者中无此相关性(r=-0.20;P=0.21)。年龄增加(P=0.014)、糖尿病史(P=0.043)、入院血糖>140mg/dL(P=0.002)以及早期再闭塞(P=0.004)是再灌注患者预后不良的相关因素。逻辑回归模型显示,尽管tPA诱导了再通,但仅入院血糖值>140mg/dL(优势比,8.4;95%CI,1.76至40.02;P=0.005)是预后不良的独立预测因素。在MCA闭塞持续6小时的患者中,单因素分析显示基线NIHSS评分>15分(P=0.011)和MCA近端闭塞(P=0.039)是与预后不良相关的变量。在逻辑回归模型中,对于未实现再灌注的tPA治疗患者,仅NIHSS评分>15分(优势比,11.9;95%CI,1.48至97.1;P=0.032)仍然是3个月时预后不良和功能依赖的独立预测因素。

结论

再灌注前的高血糖可能部分抵消早期血流恢复的有益作用,这导致高血糖患者尽管有tPA诱导的再通但预后更差。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验